8legs: Fda

Your Followed Topics

#1 out of 3

Outset Medical gains FDA clearance for its next-gen Tablo platform, marking a key regulatory milestone.
The new Tablo meets FDA's top cybersecurity standards, emphasizing security enhancements.
Upgrades improve reliability and connectivity while extending maintenance intervals.
Shipments to customers are expected to begin in the second quarter of 2026.
Current users may upgrade to the new cybersecurity platform as part of the rollout.

Vote 0

#2 out of 3

health10h ago

Navitas Organics recalls specific 8-ounce Organic Chia Seeds nationwide amid potential contamination concerns.
The recall followed a supplier alert and covers products sold at Whole Foods and online retailers like Amazon.
Consumers are urged to discard the recalled chia seeds or return them for a refund.
The lots affected include W31025283 and several others, with best-by dates from late April to late May 2027.
FDA notes no illnesses or adverse health events have been reported in connection with the recall.
The recall does not affect other Navitas Organics products at this time.
Navitas Organics initiated the recall as a precautionary measure after supplier notification.
The items were sold nationwide in stores and online, including Whole Foods and Amazon.
Chia seeds are sold in 8-ounce stand-up pouches with UPC 858847000284.
FDA describes Salmonella as a serious infection risk, especially for vulnerable groups.

Vote 0

#3 out of 3

The FDA has greenlit a gene therapy study by Life Biosciences, marking a notable regulatory milestone in longevity research.
The trial aims at a near-total reset of cells, a concept central to theories about aging and potential reversal.
R&D cell and gene therapy developments remain a focal point as the field moves toward experimental therapies and regulatory scrutiny.
The report notes additional near-term developments, including mid-stage obesity results and phase 3 inquiries into gene editing.
Insilico and other firms are highlighted for recent deal activity linked to data delivery and clinical timing.
The exclusive has implications for investors and policymakers tracking the pace of regenerative medicine.
The article emphasizes the high-stakes nature of aging research and potential healthcare impacts.
Readers are invited to sign up for full access to the exclusive content and related newsletters.
The piece compiles current industry context around biotech advances in gene therapy and longevity.

Vote 0

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access

Personalized Feed

Full Experience

By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.